Alpha 2.0
Login Register
» Authors » Sofiya Latifyan

Sofiya Latifyan

Explore the profile of Sofiya Latifyan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 155
Followers 0
Related Specialties
General Medicine
Oncology
Pharmacology
Top 10 Co-Authors
Olivier Michielin
Solange Peters
Dominik Berthold
Nuria Mederos
Hasna Bouchaab
Rita De Micheli
Athina Stravodimou
Apostolos Sarivalasis
Khalil Zaman
Alexandre Wicky
Published In
Rev Med Suisse
J Immunother Cancer
Front Oncol
ESMO Open
JCO Clin Cancer Inform
Affiliations
Soon will be listed here.
Recent Articles
1.
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Chiffelle J, Barras D, Petremand R, Orcurto A, Bobisse S, Arnaud M, et al.
Immunity . 2024 Sep; 57(10):2466-2482.e12. PMID: 39276771
Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) has inconsistent clinical responses. To better understand determinants of therapeutic success, we tracked TIL clonotypes from baseline tumors to...
2.
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, et al.
Nat Commun . 2024 May; 15(1):3664. PMID: 38693123
The application of mammalian target of rapamycin inhibition (mTORi) as primary prophylactic therapy to optimize T cell effector function while preserving allograft tolerance remains challenging. Here, we present a comprehensive...
3.
Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S, Haanen J
Med . 2024 Apr; 5(4):288-290. PMID: 38614074
KEYNOTE-942 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear...
4.
[Oncology: what's new in 2023]
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, et al.
Rev Med Suisse . 2024 Jan; 20(856-7):80-87. PMID: 38231107
The oncology field continues its remarkable evolution over the years, with promising advances leading to innovative and individualized treatments. The development of new molecules, the identification of new therapeutic targets...
5.
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series
Vicino A, Hottinger A, Latifyan S, Boughdad S, Becce F, Prior J, et al.
J Neurol . 2023 Dec; 271(4):1947-1958. PMID: 38141128
Background: Immune checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancers, but often cause immune-related adverse events (irAEs). Among neurological irAEs, myositis is the most frequently reported. Our aim...
6.
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial
da Silva Lopes A, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, et al.
JMIR Res Protoc . 2023 Oct; 12:e48386. PMID: 37851498
Background: Management of severe symptomatic immune-related adverse events (IrAEs) related to immune checkpoint inhibitors (ICIs) can be facilitated by timely detection. As patients face a heterogeneous set of symptoms outside...
7.
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
da Silva Lopes A, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, et al.
Support Care Cancer . 2023 Jul; 31(8):484. PMID: 37480546
Purpose: The use of electronic patient-reported outcome (ePRO) data in routine care has been tied to direct patient benefits such as improved quality of care and symptom control and even...
8.
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy
Courlet P, Abler D, Guidi M, Girard P, Amato F, Violi N, et al.
CPT Pharmacometrics Syst Pharmacol . 2023 Jun; 12(8):1170-1181. PMID: 37328961
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic...
9.
[Endometrial cancer in the crossroads of modernity and immunotherapy]
Giacomuzzi Moore B, Liapi A, Dolcan A, Kakourou A, Masmoudi S, Latifyan S, et al.
Rev Med Suisse . 2023 May; 19(827):944-949. PMID: 37195107
Frequent and with an increasing incidence in some territories, endometrial cancer is a complex disease leading to significant morbidity among affected patients. After years of research and the implementation of...
10.
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging
Abler D, Courlet P, Dietz M, Gatta R, Girard P, Munafo A, et al.
JCO Clin Cancer Inform . 2023 May; 7:e2200126. PMID: 37146261
Purpose: A semiautomated pipeline for the collection and curation of free-text and imaging real-world data (RWD) was developed to quantify cancer treatment outcomes in large-scale retrospective real-world studies. The objectives...